VEGFR2/CD309 Protein (AA 20-764, C-Term) (Fc Tag)

Catalog No. ABIN2666871

Recombinant VEGFR2/CD309 protein expressed in HEK-293 Cells.

Quick Overview for VEGFR2/CD309 Protein (AA 20-764, C-Term) (Fc Tag) (ABIN2666871)

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Application: Flow Cytometry (FACS)

Purity: > 95 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 20-764, C-Term

Purification tag / Conjugate: This VEGFR2/CD309 protein is labelled with Fc Tag.

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 = 10 - 40 ng/ml, corresponding to a specific activity of 0.25 - 1 x 105 units/mg, as determined by inhibition of HUVEC cell proliferation induce by 5 ng/ml of VEGF165.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS, pH 7.2.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Alternative Name: VEGFR2

Background: The VEGF family includes five members, VEGFA (VEGFA165), VEGFB, VEGFC, VEGFD, and placenta growth factor (PlGF). Structurally, these growth factors are homodimers, although heterodimers have been described that are composed of VEGFA and PIGS. There are three VEGF receptor tyrosine kinases: VEGFR1 (Flt1), VEGFR2 (Flk1), and VEGFR3 (Flt4). The expression of these receptors is overlapping, nevertheless, a distribution pattern has been reported: VEGFR1 is expressed on monocytes and macrophages, VEGFR2 on vascular endothelial cells, and VEGFR3 on lymphatic endothelial cells. VEGFR2 also binds proteolytically processed VEGFC and VEGFD. VEGFR2 is the major mediator of the signaling cascades that regulate endothelial cell functions including: proliferation, migration and differentiation. Soluble VEGFR2 was initially identified in mouse and human plasma resulting from an endothelial cell surface proteolytic cleavage. VEGFA stimulates ADAM17-dependent shedding of VEGFR2, also, its shedding is stimulated by phorbol ester (PMA) and the calcium ionophore, ionomycin. Soluble VEGF1 and VEGFR2 act as decoy receptors for VEGFA, regulating the availability of VEGFA. In addition, alternative splicing of VEGFR2 produces soluble VEGFR2 that binds VEGFC and subsequently prevents lymphangiogenesis. It has been reported that decreased levels of VEGFR2 in the plasma of preeclamptic women may serve as a marker of endothelial cell dysfunction.

Molecular Weight: The 976 amino acid recombinant protein has a predicted molecular mass of approximately 109 kDa. The DTT-reduced and non-reduced glycosylated protein migrate at approximately 200 kDa and >250 kDa respectively by SDS-PAGE. The N-terminal amino acid is Ala.

Pathways: RTK Signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling